The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.
This treatment study is an16-weeks outpatient clinical trial where subjects will get medication, which might help them to reduce or stop their drinking or a placebo ( placebo is a capsule that looks the same as the investigational drug, but has no real medication. It is a "sugar pill"). This study will recruit and randomize subjects who have expressed an interest in receiving treatment for alcohol dependence. Upon enrollment into this study there will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
MUSC Center For Drug And Alcohol Programs is conducting an alcohol research study investigating the effects of a medication in response to alcohol. Individuals (ages 21-40) who complete the study will be paid for their participation. This study does not involve alcohol treatment. For more information, call Mark at 792-1222.
Looking for men and women ages 18 to 70 who are alcohol dependent and currently drink and are otherwise generally healthy. The treatment period is 16 weeks with medication called naltrexone or placebo taken daily. There will be 9 visits during the treatment period and two follow up visits on weeks 28 and 40. Participants will be seen by a medical provider (MD or nurse), blood tests will be done prior to and during participation.